Xencor, Inc. (XNCR)
Designs engineered antibodies to fight cancer and autoimmune diseases
$19.97+0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+150.3%
The outlook
Xencor is trading near the upper end of its 52-week range, sitting above both its 50- and 200-day moving averages. Analyst consensus leans strongly bullish, with an average price target about 42% above the current price. The stock shows solid technical positioning, though valuations reflect elevated expectations from the research community.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 12 analysts
Price trendAbove its 50- & 200-day averages
52-week range91% of the way from its 52-week low to high
Price targetAvg target +42% vs current price
Analyst price target
~12-month · 12 analysts$28.33average target+41.9% vs now
Now $19.97
Low $14.00High $43.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.48B
52-wk high
$21.26
52-wk low
$6.92
50-day avg
$14.03
200-day avg
$13.66
Trailing P/E
—